BBOT vs BR · $610.4M cap vs P/E 16, rev $6.89B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus Broadridge Financial Solutions Inc (BR) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Broadridge Financial Solutions Inc (BR) is a information technology services company listed on US.
BBOT does not have a complete income-statement cache yet.
Latest reported BR revenue for 2025-06-30 was $6.89B. Net income was $839.5M. Revenue was up 5.9% from 2024-06-30 to 2025-06-30. BR currently screens at market cap $17.65B and trailing P/E 16.3.
BBOT currently screens at market cap $610.4M. BR currently screens at market cap $17.65B and trailing P/E 16.3.
Not investment advice. Open the BBOT and BR stock pages for the full models.
Not investment advice.